<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640444</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-12-02</org_study_id>
    <secondary_id>2012-000840-90</secondary_id>
    <nct_id>NCT01640444</nct_id>
  </id_info>
  <brief_title>Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and &lt; 3 Circulating Tumor Cells (CTC)</brief_title>
  <acronym>VISNU-2</acronym>
  <official_title>Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and &lt; 3 Circulating Tumor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy
      of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS
      wild-type metastatic colorectal carcinoma and &lt; 3 circulating tumor cells
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical Resection (R0) surgery rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC count basal and correlate to PFS, OS, RR</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI+bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI + cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI + bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg iv, followed by
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI + cetuximab</intervention_name>
    <description>Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly
FOLFIRI:
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's Informed consent in written.

          2. Age between 18-70 years old.

          3. ECOG 0-1.

          4. Life expectancy of at least 3 months.

          5. Histological confirmation of adenocarcinoma of the colon or rectum.

          6. Sample of tumour tissue available for evaluation of genes RAS, BRAF and PI3K. To be
             included in the study patients should present &lt; 3 CTC in peripheral blood and RAS
             wild-type present in the sample of tumor tissue.

          7. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion
             following RECIST criteria v 1.1 (non suitable for radical surgery at the inclusion
             time).

          8. Prior radiotherapy is allowed but must be completed at least 4 weeks before
             randomization (if applicable).

          9. Adequate bone marrow, liver and renal function.

         10. Women of childbearing potential must have a negative serum or urine pregnancy test.
             Postmenopausal women must have been amenorrheic for at least 12 months.Both men and
             women participating in this study must use adequate contraception.

         11. Subject must have the ability, in the opinion of the investigator, to comply with all
             the study procedures and follow-up examinations.

        Exclusion Criteria:

          1. Previous chemotherapy for metastatic disease.

          2. Prior treatment with Bevacizumab, or EGFR inhibitors

          3. Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment,
             surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks
             before randomization.

          4. Use of any investigational drug within 4 weeks before start the treatment.

          5. Clinical or radiographic evidence of brain metastasis.

          6. Uncontrolled hypertension (systolic blood pressure &gt;150 mmHg and/or diastolic blood
             pressure &gt;100 mmHg on repeated measurement) despite optimal medical management.

          7. Previous history of hypertensive encephalopathy or hypertensive crises.

          8. Current or history of peripheral neuropathy &gt; or equal to 1 NCICTCAE.

          9. Patients classified as fragile according to criteria listed in the protocol.

         10. Significant cardiovascular disease (e.g. AVC, myocardial infarction, within 6 months
             before randomization). Unstable angina, congestive heart failure New York Heart
             Association (NYHA) â‰¥ class II, arrhythmia that requires treatment within 3 months
             before randomization.

         11. Significant vascular disease (e.g. aortic aneurism requiring surgical intervention,
             pulmonary embolic, peripheral arterial thrombosis) within 6 months before
             randomization.

         12. Previous history of significant haemorrhage /severe, within 1 month before
             randomization.

         13. Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks
             before randomization.

         14. Large bore needle biopsy of a major organ within 14 days before randomization.
             Placement of central venous access port &gt; or equal to 7 days before randomization is
             permitted.

         15. Evidence or history of bleeding diathesis or coagulopathy.

         16. INR &gt;1.5 within 14 days prior to starting study treatment. EXEMPTION: patients on full
             anticoagulation must have an in-range INR[usually between 2-3]. Any anticoagulation
             therapy must be at stable dosing prior to enrolment.

         17. History of previous abdominal fistula or gastrointestinal perforation within 6 months
             before randomization.

         18. Serious non-healing wound, ulcer or bone fracture.

         19. Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory
             disease.

         20. History of uncontrolled convulsive crises.

         21. History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.

         22. Chronic, actual o recent use (10 days prior first drug administration) of
             acetylsalicylic acic (aspirin) &gt; 325 mg/day or clopidogrel (75mg/day) or other
             treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted &lt; or
             equal to 325 mg/day).

         23. Urinary protein excretion &gt; or equal to 2+ (dipstick). If &gt; or equal 2 g proteinuria
             is detected with dipstick, a 24-hour period urine test will be performed and the
             result should be &lt; or equal to 1 g/24 hours to permit the inclusion of the patient in
             the clinical trial

         24. Known human immunodeficiency virus infection or chronic hepatitis B or C infection or
             other uncontrolled, severe concurrent infection .

         25. Current infection &gt; or equal to Grade 2 (NCI-CTCAE).

         26. Any previous or concurrent cancer different to colorectal carcinoma within 5 years
             before to start the treatment. Subjects with successfully treated, non-invasive
             cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to
             participate in the clinical trial. Or those cancer treated with curative intention
             without disease evidence in the last 5 years at least

         27. Known or suspected allergy or hypersensitivity to any component of bevacizumab,
             cetuximab, irinotecan, or 5-FU/LV.

         28. Any medical, psychological, or social condition that may interfere with the subject's
             participation in the study or evaluation of the study results.

         29. Any psychological, familial or geographic situation that interferes in the adequate
             follow-up and adherence to the study protocol.

         30. Women who are pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo DÃ­az-Rubio, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital ClÃ­nico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Aranda, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina SofÃ­a</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Sastre, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital ClÃ­nico San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Digestive Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal carcinoma</keyword>
  <keyword>BRAF and PIK3K</keyword>
  <keyword>FOLFIRI -Bevacizumab -Cetuximab</keyword>
  <keyword>circulating tumor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

